The Filing Desk

Anteris Technologies Global vs Pulse Biosciences

Anteris Technologies Global AVR · Pulse Biosciences PLSE · Health Care Equipment

Anteris Technologies Global reported revenue of $2 million in fiscal 2025, 6.3 times Pulse Biosciences' $0 million in fiscal 2025. Anteris Technologies Global had an operating margin of -4908.2%, against -21982.6% at Pulse Biosciences. Free cash flow was −$80 million at Anteris Technologies Global and −$54 million at Pulse Biosciences.

Side by side

Anteris Technologies GlobalPulse Biosciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$2M$0M
Revenue growth−29.2%—
Revenue growth a year, last 5 years——
Gross margin70.3%−54.0%
Operating margin−4,908.2%−21,982.6%
Net margin−4,921.3%−20,794.6%
Free cash flow−$80M−$54M
Free cash flow margin−4,169.2%−15,553.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count82.2%15.4%
Last close$5.42$50.44
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score—3 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Anteris Technologies GlobalPulse Biosciences
Operating margin
Percent of revenue
Anteris Technologies GlobalPulse Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Anteris Technologies GlobalPulse Biosciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Anteris Technologies Global and Pulse Biosciences pages.